Blog

The below Parliamentary question was asked by Lord Freyberg on 2016-02-22.

To ask Her Majesty’s Government when the first results from the prostate patient reported outcomes, and in particular for incontinence rates, will be available from the National Prostate Cancer Audit.

Lord Prior of Brampton

The proportion of men diagnosed with locally advanced prostate cancer between 2010 and 2013 (the Audit period) who had radical treatment, and the proportion who had a hospital length of stay over three days and who required an emergency readmission within 90 days following an operation, are presented by health region in the attached headed Table 1.

It should be noted that the results presented are based on an analysis of data from the English Cancer Registry linked to the Hospital Episode Statistics. These data were collected before the start of the National Prostate Cancer Audit (NPCA) in April 2013.

The number of radical prostatectomies undertaken in men diagnosed between 2010 and 2013, and the proportion of men who had a hospital length of stay over three days and who had an emergency readmission within 90 days following an operation, are presented in the attached headed Table 2. The results of 56 men included in the data set used to generate Figure 8 in the NPCA Annual Report 2015 could not be included in Table 2. Of these men, 37 were treated in National Health Service trusts that treated fewer than five patients during the Audit period; and for 19 patients it was not possible to identify the NHS trust where they had undergone treatment without incurring disproportionate cost.

The first results for the patient-reported outcomes of men who were diagnosed with prostate cancer between 1 April 2014 and 30 September 2014, and who underwent radical treatment (prostatectomy, external beam radiation, brachytherapy, cryotherapy, and high-intensity focused ultrasound), will be included in the NPCA’s Annual Report 2016, which is due to be published in the last quarter of 2016. These results will include incontinence rates.

Men who had radical prostate cancer treatment were invited to complete a questionnaire about their experiences of care as well as about treatment outcomes, 18 months after the date of diagnosis. It was decided that questionnaires should be sent out at this time after diagnosis because it can take more than one year for men who have radiotherapy, in combination with androgen deprivation therapy, to complete their treatment. Subsequently, it will take at least three months for men to fully recover from the transient side effects of the radiotherapy. In order to include all men and to measure the final treatment outcome – rather than outcomes still affected by the transient side effects – an 18-month period was chosen.

The below Parliamentary question was asked by Lord Freyberg on 2016-02-22.

To ask Her Majesty’s Government for those trusts carrying out radical prostate cancer treatments, what were the results for the following responses to the most recent National Prostate Cancer Audit: (1) the number of operations undertaken in the audit period, (2) the proportion of those operations with a hospital length of stay of over three days, and (3) the proportion of those operations requiring emergency readmission within 90 days.

Lord Prior of Brampton

The proportion of men diagnosed with locally advanced prostate cancer between 2010 and 2013 (the Audit period) who had radical treatment, and the proportion who had a hospital length of stay over three days and who required an emergency readmission within 90 days following an operation, are presented by health region in the attached headed Table 1.

It should be noted that the results presented are based on an analysis of data from the English Cancer Registry linked to the Hospital Episode Statistics. These data were collected before the start of the National Prostate Cancer Audit (NPCA) in April 2013.

The number of radical prostatectomies undertaken in men diagnosed between 2010 and 2013, and the proportion of men who had a hospital length of stay over three days and who had an emergency readmission within 90 days following an operation, are presented in the attached headed Table 2. The results of 56 men included in the data set used to generate Figure 8 in the NPCA Annual Report 2015 could not be included in Table 2. Of these men, 37 were treated in National Health Service trusts that treated fewer than five patients during the Audit period; and for 19 patients it was not possible to identify the NHS trust where they had undergone treatment without incurring disproportionate cost.

The first results for the patient-reported outcomes of men who were diagnosed with prostate cancer between 1 April 2014 and 30 September 2014, and who underwent radical treatment (prostatectomy, external beam radiation, brachytherapy, cryotherapy, and high-intensity focused ultrasound), will be included in the NPCA’s Annual Report 2016, which is due to be published in the last quarter of 2016. These results will include incontinence rates.

Men who had radical prostate cancer treatment were invited to complete a questionnaire about their experiences of care as well as about treatment outcomes, 18 months after the date of diagnosis. It was decided that questionnaires should be sent out at this time after diagnosis because it can take more than one year for men who have radiotherapy, in combination with androgen deprivation therapy, to complete their treatment. Subsequently, it will take at least three months for men to fully recover from the transient side effects of the radiotherapy. In order to include all men and to measure the final treatment outcome – rather than outcomes still affected by the transient side effects – an 18-month period was chosen.

The below Parliamentary question was asked by Lord Freyberg on 2016-02-22.

To ask Her Majesty’s Government what were the results, by health region, for the data in the most recent National Prostate Cancer Audit (NPCA), as shown in figure 8 of the NPCA Second Year Annual Report, regarding the proportion of (1) men with locally advanced disease undergoing radical prostate cancer treatment, (2) those operations with a hospital length of stay of over three days, and (3) those operations requiring emergency readmission within 90 days.

Lord Prior of Brampton

The proportion of men diagnosed with locally advanced prostate cancer between 2010 and 2013 (the Audit period) who had radical treatment, and the proportion who had a hospital length of stay over three days and who required an emergency readmission within 90 days following an operation, are presented by health region in the attached headed Table 1.

It should be noted that the results presented are based on an analysis of data from the English Cancer Registry linked to the Hospital Episode Statistics. These data were collected before the start of the National Prostate Cancer Audit (NPCA) in April 2013.

The number of radical prostatectomies undertaken in men diagnosed between 2010 and 2013, and the proportion of men who had a hospital length of stay over three days and who had an emergency readmission within 90 days following an operation, are presented in the attached headed Table 2. The results of 56 men included in the data set used to generate Figure 8 in the NPCA Annual Report 2015 could not be included in Table 2. Of these men, 37 were treated in National Health Service trusts that treated fewer than five patients during the Audit period; and for 19 patients it was not possible to identify the NHS trust where they had undergone treatment without incurring disproportionate cost.

The first results for the patient-reported outcomes of men who were diagnosed with prostate cancer between 1 April 2014 and 30 September 2014, and who underwent radical treatment (prostatectomy, external beam radiation, brachytherapy, cryotherapy, and high-intensity focused ultrasound), will be included in the NPCA’s Annual Report 2016, which is due to be published in the last quarter of 2016. These results will include incontinence rates.

Men who had radical prostate cancer treatment were invited to complete a questionnaire about their experiences of care as well as about treatment outcomes, 18 months after the date of diagnosis. It was decided that questionnaires should be sent out at this time after diagnosis because it can take more than one year for men who have radiotherapy, in combination with androgen deprivation therapy, to complete their treatment. Subsequently, it will take at least three months for men to fully recover from the transient side effects of the radiotherapy. In order to include all men and to measure the final treatment outcome – rather than outcomes still affected by the transient side effects – an 18-month period was chosen.

The below Parliamentary question was asked by Lord Freyberg on 2016-02-22.

To ask Her Majesty’s Government, further to the Written Answers by Lord Prior of Brampton on 4 February (HL5344) and on 11 February (HL5970), how many of the 8,000 expected clinical reports are in the cancer part of that project, as compared to the rare disease; and in the cancer part of that project, how many are planned for delivery by the end of (1) March, (2) June, and (3) September.

Lord Prior of Brampton

The 100,000 Genomes project cancer pipeline is still being evaluated and the precise proportion of the reports that will relate to cancer is not currently known.